Amgen Inc (Amgen) discovers, develops, manufactures, and markets novel human medicines with focus on disease areas such as cancer, inflammation, cardiovascular disease, nephrology, bone health and neurological disorders. The company uses advanced human genetics to unravel the complications of disease and understand the fundamentals of human biology. It operates through one business segment: Human Therapeutics (HT). The company's portfolio demonstrates its focus on improving the quality of life for patients and overall health outcomes.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

R&D efforts enable Amgen to develop novel human medicines for treating serious illnesses related to oncology/hematology, cardiovascular disease, inflammation, bone health, nephrology and neurological conditions. Its pipeline includes a mix of novel molecules, and biosimilars. As of FY2023, the company’s pipeline had 54 candidates (13 in Phase I; 12 in Phase II; and 29 in Phase III) with strong genetic support. In FY2023, the company spent US$4,755 million on R&D, which as a percentage of revenue, stood at 16.9%. It has major R&D centers in the US (including Cambridge, Massachusetts, and Thousand Oaks and San Francisco, California), Canada, China, Germany, Iceland, Japan, the UK and other countries. It owns numerous US and foreign patents covering pharmaceutical products and their uses, product manufacturing processes and pharmaceutical formulations.